Foistar®(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra®(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients

Jae-Phil Choi, Hyoung-Jun Kim, Jumi Han, SuJung Park, JinJoo Han
doi: https://doi.org/10.1101/2020.12.10.20240689

Data Availability

All data referred in the manuscript are provided in the results and supplementary materials.

Back to top
Posted December 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Foistar®(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra®(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients
Jae-Phil Choi, Hyoung-Jun Kim, Jumi Han, SuJung Park, JinJoo Han
medRxiv 2020.12.10.20240689; doi: https://doi.org/10.1101/2020.12.10.20240689
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area